Plant peptide could prevent onset of multiple sclerosis

March 29, 2016

MedUni Vienna has made a crucial development in the treatment of Multiple Sclerosis (MS): Together with his team and the research group led by Gernot Schabbauer, international partners from Australia, Germany and Sweden, Christian Gruber, Chief Researcher at the Center for Physiology and Pharmacology has demonstrated in an animal model that, following treatment with a specially synthesized plant peptide (cyclotide), there is no further progression of the usual clinical signs of multiple sclerosis. Gruber: "The one-off oral administration of the active agent brought about a great improvement in symptoms. There were no further attacks of the disease. This could slow down the course of the disease in general."

MS is a chronic inflammatory autoimmune disease of the central , in which the insulating myelin sheaths around the nerve fibres are destroyed. The disease progresses in the form of attacks or episodes and is currently incurable. An episode is defined by the occurrence of new symptoms or flare-ups of pre-existing ones. Each episode is associated with immediate or deferred deterioration in the patient's condition. The mechanism of inflammation in the nervous system is partially understood. Based on this knowledge, there are treatments to slow down progression of the disease but these have significant side effects, particularly in long-term therapy. It is estimated that around 2.5 million people are affected by MS worldwide, around 8,000 of these in Austria.

The discovery made by the Viennese scientists now offers hope that the disease can be halted at a very early stage or, at the very least, its progression greatly retarded. "As soon as functional neurological problems occur and an MRI (Magnetic Resonance Imaging) scan identifies early pathological changes in the central nervous system, the drug can be given as a basic therapy. In an for MS, symptoms were considerably reduced by the oral administration of cyclotides. It is therefore possible that we could extend the interval between episodes or possibly prevent an onset of the disease," say Gruber and Schabbauer, summing up of the central finding of the study, which has now been published in the leading journal PNAS.

On the basis of this development, MedUni Vienna, together with Freiburg University Hospital has filed patent applications in several countries and licensed them out to Cyxone, a company they have set up to carry out further development (www.cyxone.com). The aim of this collaboration is to develop a safe, orally active drug for treating . A Phase I clinical trial for this could start at the end of 2018, says Gruber.

Cyclotides: Easily available and orally deliverable

Cyclotides are macrocyclic plant peptides that can be isolated from all the main plant families (e.g. coffee plants, cucurbits or even grasses and plants of the nightshade family) and therefore represent a large and wide-ranging group of natural substances. A further advantage: the medicine obtained from them can be taken orally. Many of the current MS treatments in common use have to be administered intravenously.

The mode of action of cyclotides was discovered three years ago, also by scientists at MedUni Vienna, in collaboration with researchers from Freiburg University Hospital: they suppress the messenger substance interleukin-2 and hence the division of T cells, which act as "killer" or "helper" cells in the human immune system response. Hence, cyclotides could also possibly be used to treat other diseases characterized by an overactive, misdirected immune response, such as rheumatoid arthritis, for example.

Explore further: Immune suppression through cyclic plant peptides

More information: Kathrin Thell et al. Oral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis, Proceedings of the National Academy of Sciences (2016). DOI: 10.1073/pnas.1519960113

Related Stories

Immune suppression through cyclic plant peptides

March 1, 2012

A team of researchers at the MedUni Vienna, together with scientists from the University Hospital of Freiburg, has decoded a mechanism in cyclic plant peptides, known as cyclotides, from the family of coffee plants (Rubiaceae) ...

How multiple sclerosis can be triggered by brain cell death

December 14, 2015

Multiple sclerosis (MS) may be triggered by the death of brain cells that make the insulation around nerve fibers, a surprising new view of the disease reported in a study from Northwestern Medicine and The University of ...

Study suggests remarkable approach to MS treatment

February 8, 2016

(Medical Xpress)—Multiple sclerosis (MS) is an autoimmune inflammatory disorder in which the immune system attacks the myelin sheath enveloping and insulating the nerves. A progressive disease that often results in severe ...

Recommended for you

Scientists develop new drug screening tool for dystonia

December 8, 2016

Duke University researchers have identified a common mechanism underlying separate forms of dystonia, a family of brain disorders that cause involuntary, debilitating and often painful movements, including twists and turns ...

Honeybee memories: Another piece of the Alzheimer's puzzle?

December 8, 2016

A breakdown of memory processes in humans can lead to conditions such as Alzheimer's and dementia. By looking at the simpler brain of a honeybee, new research published in Frontiers in Molecular Neuroscience, moves us a step ...

3 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

katesisco
5 / 5 (1) Mar 29, 2016
Searching the internet I discovered that a combination of plant enzymes and serrapeptase was significant in reducing the numbness in my hands along with several other herbals as well as HCL for the stomach.
dirk_bruere
5 / 5 (1) Mar 29, 2016
Coming to a doctor near you, in about 15 years after the patents and legal stuff is done
SusejDog
not rated yet Mar 31, 2016

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.